Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 19/20 | 0.80 |
| ▸ | AKR1C2 | P52895 | 19/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902692 | 0.90 | AKR1C3 (0.64) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL9594214 | 0.89 | AKR1C3 (1.00) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL30701240 | 0.89 | AKR1C3 (1.00) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL293867 | 0.86 | AKR1C3 (1.00) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL9594324 | 0.85 | AKR1C3 (1.00) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL22169115 | 0.84 | AKR1C3 (0.80) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL296232 | 0.84 | AKR1C3 (0.80) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL15397409 | 0.82 | AKR1C3 (0.60) | AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL9595058 | 0.82 | AKR1C3 (1.00) | AKR1C3AKR1C2MEN1LMNAKMT2A | |
| SCHEMBL902254 | 0.81 | AKR1C3 (0.72) | AKR1C3AKR1C2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| EP-2621929-A1 | NOVEL ACRIDINE DERIVATIVES | Pharminox Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012042265-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012042265-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | TERT, NAT10, POT1 | AKR1C3 1249/4885AKR1C2 991/4885MEN1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.